Elucidation of the mechanism how Vandetanib kills RET-positive lung cancer cells

Research Project

Project/Area Number	26830121
Research Category	Grant-in-Aid for Young Scientists (B)
Allocation Type	Multi-year Fund
Research Field	Tumor therapeutics
Research Institution	National Cancer Center Japan
Principal Investigator	Makinoshima Hideki 国立研究開発法人国立がん研究センター, 先端医療開発センター, 研究員 (30510573)
Project Period (FY)	2014-04-01 – 2016-03-31
Project Status	Completed (Fiscal Year 2015)
Budget Amount *help	¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000) Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000) Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Keywords	融合遺伝子 / 肺がん / 薬剤耐性 / シグナル伝達 / トランスレーショナルリサーチ / 遺伝子発現 / RET / がんの代謝
Outline of Final Research Achievements	Rearrangements of the proto-oncogene RET were newly identified potential driver mutations in lung adenocarcinoma. We had found the cell line LC2/ad harboring RET fusion gene and Vandetanib was the most effective compound to inhibit LC2/ad cells by down-regulating RET fusion protein. To elucidate the mechanism how Vandetanib efficiently kills RET-positive lung cancer cells, we have identified Vandetanib-target molecules in addition to RET and established Vandetanib-resistant cell lines.

Report

(3 results)